FDA-approved

Sexual & reproductive

Bremelanotide

Evidence

FDA approved

Class

Melanocortin receptor agonist

/

Bremelanotide

KEY TAKEAWAY

Bremelanotide is a melanocortin receptor agonist approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is used as needed about 45 minutes before sexual activity.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

A melanocortin receptor agonist acting on the brain

Approved for

Hypoactive sexual desire disorder in premenopausal women

Key fact

Increased desire scores compared with placebo in phase 3 trials

Route

Injection before activity

Evidence strength

FDA approved

What it is

What it is

Bremelanotide, sold as Vyleesi, is a synthetic peptide related to alpha-MSH, delivered with an autoinjector.

How it works

How it works

It activates melanocortin receptors in the brain, which are involved in sexual desire and arousal.

Regulatory status

Regulatory status

The FDA approved bremelanotide in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder.

What it is used for

What it is used for

Treatment of low sexual desire that causes distress in premenopausal women, when not explained by another condition.

Side effects and risks

Side effects and risks

Nausea is the most common effect. Flushing, headache and a short-lived rise in blood pressure can occur. Skin darkening has been reported.

Citations

Citations

Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol. 2019;134:899-908.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo